Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post‐transplant cyclophosphamide for treatment of high‐risk myeloid neoplasms in children: A retrospective study
Pediatric Blood & Cancer · 2023
DOI: 10.1002/pbc.30659 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2023. Verfasst von Shan-Shan Qi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pediatric Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Hematologic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Post‐transplant cyclophosphamide (PTCy) has been recommended for prevention of graft‐versus‐host disease (GvHD) following haploidentical hematopoietic cell transplantation (haplo‐HCT) for treatment of malignant blood diseases, but disease relapse remains a problem. Although donor lymphocyte infusion (DLI) is reported to be effective for treating post‐transplantation relapse, the efficacy and safety of prophylactic‐DLI (pro‐DLI) post haplo‐HCT, and PTCy in pediatric patients with hematological malignancies is unknown.
Methods
We retrospectively analyzed the outcomes of 54 pediatric patients with high‐risk myeloid neoplasms who received a PTCy regimen for GvHD prophylaxis and pro‐DLI after haploidentical peripheral blood stem cell transplantation. The high‐risk myeloid neoplasms in this cohort included acute myeloid leukemia ( n = 46) and myelodysplastic syndromes ( n = 8).
Results
Median follow‐up was for 19.7 (range: 3.4–46.6) months. The cumulative incidences of grade II–IV and III–IV acute GvHD were 37.0% (95% CI: 22.7%–48.7%) and 16.7% (95% CI: 6.1%–26.0%), respectively. There were no graft‐failure events, and the 2‐year rate of moderate/severe chronic GvHD was 8.1% (95% CI: 0%–16.7%). The 2‐year non‐relapse mortality, relapse, disease‐free survival, GvHD‐free relapse‐free survival, and overall survival rates were 5.1% (95% CI: 0%–11.7%), 16.6% (95% CI: 5.3%–26.6%), 78.9% (95% CI: 68.0%–91.6%), 62.2% (95% CI: 49.4%–78.3%), and 87.3% (95% CI: 78.3%–97.4%), respectively.
Conclusions
Prophylactic donor lymphocyte infusion in the setting of haploidentical hematopoietic cell transplantation with post‐transplant cyclophosphamide appears to be effective and safe in pediatric patients with high‐risk myeloid neoplasms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pediatric Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Hao Xiong
Förderung
- Natural Science Foundation of Hubei Province
Zitieren
APA
Qi, S. S., Chen, Z., Du, Y., Sun, M., Wang, Z., Long, F., Luo, L., & Xiong, H. (2023). Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post‐transplant cyclophosphamide for treatment of high‐risk myeloid neoplasms in children: A retrospective study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30659
Vancouver
Qi SS, Chen Z, Du Y, Sun M, Wang Z, Long F, et al. Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post‐transplant cyclophosphamide for treatment of high‐risk myeloid neoplasms in children: A retrospective study. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30659
BibTeX
@article{Qi2023,
author = {Qi, Shan-Shan and Chen, Zhi and Du, Yu and Sun, Ming and Wang, Zhuo and Long, Fei and Luo, Linlin and Xiong, Hao},
title = {Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post‐transplant cyclophosphamide for treatment of high‐risk myeloid neoplasms in children: A retrospective study},
journal = {Pediatric Blood & Cancer},
year = {2023},
doi = {10.1002/pbc.30659}
}
EUVIMED